137 related articles for article (PubMed ID: 37541641)
1. CPT2-mediated fatty acid oxidation inhibits tumorigenesis and enhances sorafenib sensitivity via the ROS/PPARγ/NF-κB pathway in clear cell renal cell carcinoma.
Zeng K; Li Q; Song G; Chen B; Luo M; Miao J; Liu B
Cell Signal; 2023 Oct; 110():110838. PubMed ID: 37541641
[TBL] [Abstract][Full Text] [Related]
2. CPT2 downregulation triggers stemness and oxaliplatin resistance in colorectal cancer via activating the ROS/Wnt/β-catenin-induced glycolytic metabolism.
Li H; Chen J; Liu J; Lai Y; Huang S; Zheng L; Fan N
Exp Cell Res; 2021 Dec; 409(1):112892. PubMed ID: 34688609
[TBL] [Abstract][Full Text] [Related]
3. Downregulation of CPT2 promotes proliferation and inhibits apoptosis through p53 pathway in colorectal cancer.
Liu F; Li X; Yan H; Wu J; Yang Y; He J; Chen J; Jiang Z; Wu F; Jiang Z
Cell Signal; 2022 Apr; 92():110267. PubMed ID: 35108639
[TBL] [Abstract][Full Text] [Related]
4. WY-14643 attenuates lipid deposition via activation of the PPARα/CPT1A axis by targeting Gly335 to inhibit cell proliferation and migration in ccRCC.
Wang R; Zhao J; Jin J; Tian Y; Lan L; Wang X; Zhu L; Wang J
Lipids Health Dis; 2022 Nov; 21(1):121. PubMed ID: 36384580
[TBL] [Abstract][Full Text] [Related]
5. PPARγ is dispensable for clear cell renal cell carcinoma progression.
Sanchez DJ; Steger DJ; Skuli N; Bansal A; Simon MC
Mol Metab; 2018 Aug; 14():139-149. PubMed ID: 29866440
[TBL] [Abstract][Full Text] [Related]
6. Lipid in Renal Carcinoma: Queen Bee to Target?
Tan SK; Welford SM
Trends Cancer; 2020 Jun; 6(6):448-450. PubMed ID: 32459999
[TBL] [Abstract][Full Text] [Related]
7. Upregulation of Rpn10 promotes tumor progression via activation of the NF-κB pathway in clear cell renal cell carcinoma.
Huang T; Tian W; Zhou Q; Li J; Jiang Z; Chen J; Ge C; Tian H
Acta Biochim Biophys Sin (Shanghai); 2021 Jul; 53(8):988-996. PubMed ID: 34133712
[TBL] [Abstract][Full Text] [Related]
8. HRD1 inhibits fatty acid oxidation and tumorigenesis by ubiquitinating CPT2 in triple-negative breast cancer.
Guo X; Wang A; Wang W; Wang Y; Chen H; Liu X; Xia T; Zhang A; Chen D; Qi H; Ling T; Piao HL; Wang HJ
Mol Oncol; 2021 Feb; 15(2):642-656. PubMed ID: 33207079
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of CLDN7 due to promoter hypermethylation is associated with human clear cell renal cell carcinoma progression and poor prognosis.
Li Y; Gong Y; Ning X; Peng D; Liu L; He S; Gong K; Zhang C; Li X; Zhou L
J Exp Clin Cancer Res; 2018 Nov; 37(1):276. PubMed ID: 30428910
[TBL] [Abstract][Full Text] [Related]
10. CARMA3 Transcriptional Regulation of STMN1 by NF-κB Promotes Renal Cell Carcinoma Proliferation and Invasion.
Shi D; Zhang Z; Kong C
Technol Cancer Res Treat; 2021; 20():15330338211027915. PubMed ID: 34190011
[TBL] [Abstract][Full Text] [Related]
11. SREBP1-driven lipid desaturation supports clear cell renal cell carcinoma growth through regulation of NF-κB signaling.
Yang H; Zhang X; Liu F; Fan J; Wang B; Dong C
Biochem Biophys Res Commun; 2018 Jan; 495(1):1383-1388. PubMed ID: 29183723
[TBL] [Abstract][Full Text] [Related]
12. Knocking down NSUN5 inhibits the development of clear cell renal cell carcinoma by inhibiting the p53 pathway.
Li L; Li M; Zheng J; Li Z; Chen X
Aging (Albany NY); 2023 Jun; 15(11):4757-4773. PubMed ID: 37263638
[TBL] [Abstract][Full Text] [Related]
13. Metabolic Modulation of Clear-cell Renal Cell Carcinoma with Dichloroacetate, an Inhibitor of Pyruvate Dehydrogenase Kinase.
Kinnaird A; Dromparis P; Saleme B; Gurtu V; Watson K; Paulin R; Zervopoulos S; Stenson T; Sutendra G; Pink DB; Carmine-Simmen K; Moore R; Lewis JD; Michelakis ED
Eur Urol; 2016 Apr; 69(4):734-744. PubMed ID: 26433571
[TBL] [Abstract][Full Text] [Related]
14. GPX8 regulates clear cell renal cell carcinoma tumorigenesis through promoting lipogenesis by NNMT.
Nguyen TTM; Nguyen TH; Kim HS; Dao TTP; Moon Y; Seo M; Kang S; Mai VH; An YJ; Jung CR; Kim JM; Park S
J Exp Clin Cancer Res; 2023 Feb; 42(1):42. PubMed ID: 36750850
[TBL] [Abstract][Full Text] [Related]
15. AUP1 regulates lipid metabolism and induces lipid accumulation to accelerate the progression of renal clear cell carcinoma.
Chen C; Zhao W; Lu X; Ma Y; Zhang P; Wang Z; Cui Z; Xia Q
Cancer Sci; 2022 Aug; 113(8):2600-2615. PubMed ID: 35633317
[TBL] [Abstract][Full Text] [Related]
16. PRMT1 is a novel molecular therapeutic target for clear cell renal cell carcinoma.
Wang J; Wang C; Xu P; Li X; Lu Y; Jin D; Yin X; Jiang H; Huang J; Xiong H; Ye F; Jin J; Chen Y; Xie Y; Chen Z; Ding H; Zhang H; Liu R; Jiang H; Chen K; Yao Z; Luo C; Huang Y; Zhang Y; Zhang J
Theranostics; 2021; 11(11):5387-5403. PubMed ID: 33859753
[No Abstract] [Full Text] [Related]
17. GYS1 induces glycogen accumulation and promotes tumor progression via the NF-κB pathway in Clear Cell Renal Carcinoma.
Chen SL; Huang QS; Huang YH; Yang X; Yang MM; He YF; Cao Y; Guan XY; Yun JP
Theranostics; 2020; 10(20):9186-9199. PubMed ID: 32802186
[TBL] [Abstract][Full Text] [Related]
18. G6PD facilitates clear cell renal cell carcinoma invasion by enhancing MMP2 expression through ROS‑MAPK axis pathway.
Zhang Q; Han Q; Yang Z; Ni Y; Agbana YL; Bai H; Yi Z; Yi X; Kuang Y; Zhu Y
Int J Oncol; 2020 Jul; 57(1):197-212. PubMed ID: 32319593
[TBL] [Abstract][Full Text] [Related]
19. Sphingosine kinase 1 regulates lipid metabolism to promote progression of kidney renal clear cell carcinoma.
Zhao L; Wang Z; Xu Y; Zhang P; Qiu J; Nie D; Wu G; Chen C; Chang Y; Xia Q
Pathol Res Pract; 2023 Aug; 248():154641. PubMed ID: 37467634
[TBL] [Abstract][Full Text] [Related]
20. HIF drives lipid deposition and cancer in ccRCC via repression of fatty acid metabolism.
Du W; Zhang L; Brett-Morris A; Aguila B; Kerner J; Hoppel CL; Puchowicz M; Serra D; Herrero L; Rini BI; Campbell S; Welford SM
Nat Commun; 2017 Nov; 8(1):1769. PubMed ID: 29176561
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
